ADVERSE EVENTS FOLLOWED BY COVID-19 VACCINATION AMONGST HEALTHCARE PROVIDERS

Abstract

Background:

Effective mass vaccination appears to be the only way out of COVID-19 Pandemic. Unlike every other vaccine, adverse events with COVID-19 vaccine are common. Sinopharm made two vaccines which got approval by a prestigious medical journal. The Journal for American Medical Association (JAMA) recently published the clinical trial results for two Sinopharm inoculates-code named WIVO04 and HB02. After two month of peer review the jabs were considered potent, safe and effective to curb the mortality related to COVID-19(1).WHO Strategic Advisory Group Experts (SAGE) re-evaluated the quality, safety and efficacy of both vaccines and recommended its use for people aged 18 and above. 

Methods:

We designed a single page online Performa containing most common adverse events as expected from a viral vaccine. For adverse events not mentioned in the Performa the participant could select an option ‘Other’, to document their experienced adverse event.

Results:

Out of 101 participants 54 (52.4%) experienced adverse events. Most of the adverse events were mild except one participant who had anaphylactic reaction. Six participants had COVID-19 infection within fourteen days of first dose, confirmed either through PCR or HRCT. One participant had COVID-19 infection after thirty-seven days of 2^nd dose of vaccine confirmed through PCR.

Conclusion:

Our data show that people vaccinated with Sinopharm Vaccine will have high odds to experience mild adverse events. Minor proportion of the population is at risk to develop anaphylactic reaction. The frequency to develop clinically significant COVID-19 disease decreases after second dose of vaccine.